InMode Ltd.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical devices based on proprietary radiofrequency (RF) technology. Its core product portfolio includes energy-based platforms and devices for plastic surgery, dermatology, gynecology, otolaryngology, and ophthalmology, with flagship offerings such as Morpheus8 fractional radiofrequency microneedling, Fractora, Forma RF, Lumecca IPL technology, and the recently introduced IgniteRF workstation. The company targets global markets with operations spanning North America, Europe, Asia, and Israel, where it is headquartered along with Lake Forest, California. Founded in 2008, InMode has positioned itself as a leader in innovative medical aesthetic solutions. Recent major developments include InMode's acquisition of all intellectual property assets of Viveve Medical Inc., strengthening its position in the women's health and wellness market, particularly for treatments of female stress urinary incontinence and other female wellness applications. In 2024 and 2025, the company launched next-generation products such as OPTIMAS Max and IgniteRF, which provide improved treatment efficiency and energy delivery. It also introduced a CO2 laser platform to support bundled aesthetic procedures. Additionally, InMode formed a strategic partnership with DermaFocus to incorporate Purasomes regenerative skincare products into its portfolio, enhancing outcomes for energy-based treatments. The company continues to expand its sales force globally and strengthen its international presence through subsidiary establishments and ongoing investments in research and development. InMode Ltd. remains focused on leveraging its patented RF technologies to offer innovative, minimally invasive treatment solutions across various medical aesthetic fields, supported by continuous product innovation, IP acquisitions, and strategic alliances to enhance and extend its market reach and product offerings worldwide.
InMode: My Pick For A Major Turnaround In 2026 And 2027
InMode Appoints Dr. Shlomo Nass as Chairman of the Board and Moshik Itzkovich as Chief Financial Officer
InMode to Present at Upcoming Investor Conferences and Events
InMode Ltd. (INMD) Q1 2026 Earnings Call Transcript
InMode Reports First Quarter 2026 Financial Results: Quarterly GAAP Revenue of $82 Million, Represents 5% Year-Over-Year Increase
InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
InMode Ltd. (NASDAQ:INMD) Receives Consensus Rating of “Hold” from Analysts
InMode to Present at the 25th Annual Needham Virtual Healthcare Conference
InMode Ltd. (NASDAQ:INMD) Receives Average Recommendation of “Hold” from Analysts
InMode (NASDAQ:INMD) Shares Gap Up – What’s Next?
InMode Announces New Share Repurchase Program
InMode Ltd. (INMD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
InMode to Present at Upcoming Investor Conferences
InMode (INMD) Stock Slips As Board Ends Review
InMode Announces Conclusion of Independent Transaction Committee Review
InMode: Some Green Shoots Appearing, But The Market Hasn't Noticed
InMode Ltd. (INMD) Q4 2025 Earnings Call Transcript
InMode Reports Fourth Quarter and Full Year 2025 Financial Results: Quarterly GAAP Revenue of $103.9 Million and Full Year Revenue of $370.5 Million
New York State Common Retirement Fund Has $1.27 Million Stock Position in InMode Ltd. $INMD
InMode to Participate in the 13th Annual BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference